Day: February 22, 2023

Synthesis and evaluation of [(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]cyclohexanes and 4-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]piperidines as DPP-4 inhibitors was written by Chen, Ping;Caldwell, Charles G.;Ashton, Wallace;Wu, Joseph K.;He, Huaibing;Lyons, Kathryn A.;Thornberry, Nancy A.;Weber, Ann E.. And the article was included in Bioorganic & Medicinal Chemistry Letters in 2011.Category: isoxazole This article mentions the following:

A series of 4-amino cyclohexanes and 4-substituted piperidines were prepared and evaluated for inhibition of DPP-4. Analog I displayed both good DPP-4 potency and selectivity against other proteases, while derivative II displayed long half life and modest oral bioavailability in rat. The most potent analog, 3-(5-aminocarbonylpyridyl)piperidine III, displayed excellent DPP-4 activity with good selectivity vs. other proline enzymes. In the experiment, the researchers used many compounds, for example, 5-Methyl-4-isoxazolesulfonyl chloride (cas: 321309-26-6Category: isoxazole).

5-Methyl-4-isoxazolesulfonyl chloride (cas: 321309-26-6) belongs to isoxazole derivatives. Isoxazoles also form the basis for a number of drugs, including the COX-2 inhibitor valdecoxib (Bextra) and a neurotransmitter agonist AMPA. Fe(CO)5 efficiently cleaves the N–O bond of fused isoxazolo-1,4-quinones to give the corresponding imines.All the common reducing reagents failed to open the isoxazole ring.Category: isoxazole

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Synthesis of novel isoxazoline and isoxazolidine derivatives: carboxylic acids and delta bicyclic lactones via the nucleophilic addition of bis(trimethylsilyl)ketene acetals to isoxazoles was written by Rosales-Amezcua, Saulo C.;Ballinas-Indili, Ricardo;Lopez-Reyes, Morelia E.;Rosas-Castaneda, Hector A.;Toscano, R. Alfredo;Alvarez-Toledano, Cecilio. And the article was included in ARKIVOC (Gainesville, FL, United States) in 2021.Category: isoxazole This article mentions the following:

Bis(trimethylsilyl)ketene acetals readily react with activated N-triflyl isoxazoles to selectively afford novel isoxazoline or isoxazolidine derivatives The regioselectivity of the reaction strongly depends on the substrate substituents. When the isoxazole was substituted at the 5-position by a Me or Ph group, the lactonization product, i.e., the isoxazolidine derivative, was formed as a result of double nucleophilic addition of the ketene acetal. When the isoxazole was not substituted, the main product was the corresponding carboxylic acid, i.e., the isoxazoline derivative In the experiment, the researchers used many compounds, for example, 5-Methylisoxazole (cas: 5765-44-6Category: isoxazole).

5-Methylisoxazole (cas: 5765-44-6) belongs to isoxazole derivatives. Isoxazole rings are found in some natural products, such as ibotenic acid and muscimol. Isoxazole can be synthesised via a variety of methods. Examples include via the reaction of hydroxylamine with 1,3-diketones or derivatives of propiolic acid.Category: isoxazole

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Gold-catalyzed [4+3]- and [4+2]-annulations of 3-en-1-ynamides with isoxazoles via novel 6π-electrocyclizations of 3-azahepta trienyl cations was written by Giri, Sovan Sundar;Liu, Rai-Shung. And the article was included in Chemical Science in 2018.Recommanded Product: 5765-44-6 This article mentions the following:

New gold-catalyzed [4+3]-annulations of 3-en-1-ynamides with isoxazoles afforded 4H-azepines efficiently; this process involved 6π electrocyclizations of gold-stabilized 3-azaheptatrienyl cations. In the presence of Zn(OTf)₂, the resulting 4H-azepines underwent skeletal rearrangement to furnish substituted pyridine derivatives Subsequently a new catalytic [4+2]-annulations was developed between the same 3-en-1-ynamides and isoxazoles to deliver substituted pyridine products using Au(I)/Zn(II) catalysts. The first success of the 6π electrocyclizations of heptatrienyl cations that were unprecedented in literature reports were presented. In the experiment, the researchers used many compounds, for example, 5-Methylisoxazole (cas: 5765-44-6Recommanded Product: 5765-44-6).

5-Methylisoxazole (cas: 5765-44-6) belongs to isoxazole derivatives. Isoxazoles also form the basis for a number of drugs, including the COX-2 inhibitor valdecoxib (Bextra) and a neurotransmitter agonist AMPA. As with isoxazolines, isoxazoles may be cleaved using low-valent titanium obtained from the Kulinkovich reaction.This procedure affords enaminoketones from 2,4-substituted isoxazoles.Recommanded Product: 5765-44-6

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Impact of P-glycoprotein-mediated active efflux on drug distribution into lumbar cerebrospinal fluid in nonhuman primates was written by Nagaya, Yoko;Katayama, Kazuhide;Kusuhara, Hiroyuki;Nozaki, Yoshitane. And the article was included in Drug Metabolism & Disposition in 2020.Reference of 144598-75-4 This article mentions the following:

Estimation of unbound drug concentration in the brain (Cu,brain) is an essential part of central nervous system (CNS) drug development. As a surrogate for Cu,brain in humans and nonhuman primates, drug concentration in cerebrospinal fluid (CCSF) collected by lumbar puncture is often used; however, the predictability of Cu,brain by lumbar CCSF is unclear, particularly for substrates of the active efflux transporter P-glycoprotein (P-gp). Here, we measured lumbar CCSF in cynomolgus monkey after single i.v. administration of 10 test compounds with varying P-gp transport activities. The in vivo lumbar cerebrospinal fluid (CSF)-to-plasma unbound drug concentration ratios (Kp,uu,lumbar CSF) of nonsubstrates or weak substrates of P-gp were in the range 0.885-1.34, whereas those of good substrates of P-gp were in the range 0.195-0.458 and were strongly neg. correlated with in vitro P-gp transport activity. Moreover, concomitant treatment with a P-gp inhibitor, zosuquidar, increased the Kp,uu,lumbar CSF values of the good P-gp substrates, indicating that P-gp-mediated active efflux contributed to the low Kp,uu,lumbar CSF values of these compounds Compared with the drug concentrations in the cisternal CSF and interstitial fluid (ISF) that we previously determined in cynomolgus monkeys, the lumbar CCSF were more than triple for two and all of the good P-gp substrates examined, resp. Although lumbar CCSF may overestimate cisternal CSF and ISF concentrations of good P-gp substrates, lumbar CCSF allowed discrimination of good P-gp substrates from the weak and nonsubstrates and can be used to estimate the impact of P-gp-mediated active efflux on drug CNS penetration. In the experiment, the researchers used many compounds, for example, 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4Reference of 144598-75-4).

3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4) belongs to isoxazole derivatives. Isoxazoles also form the basis for a number of drugs, including the COX-2 inhibitor valdecoxib (Bextra) and a neurotransmitter agonist AMPA. Some alternative routes for the synthesis of isoxazoles have also been developed and reported. The 2-benzoyl-2-halo-2H-azirines provide 4-haloisoxazoles in good yields after heating in toluene at reflux temperature.Reference of 144598-75-4

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Isoxazoles. XVI. Reaction of nitrous acid and 5-amino-3,4-dialkylisoxazoles was written by Kano, Hideo;Adachi, Ikuo;Yamazaki, Eiko. And the article was included in Chemical & Pharmaceutical Bulletin in 1964.Reference of 14678-05-8 This article mentions the following:

5-Amino-3,4-dialkylisoxazoles (I) treated with HNO₂ gave 4-[(3,4-dialkylisoxazol-5-yl)azo]-2-isoxazolin-5-ones (II). Thus, an aqueous solution of 7 g. NaNO₂ added to 20 g. I [R = R¹ = Me, R² = H (III)] in 70 ml. 20% HCl at <5° and the precipitate washed (H₂O) and dried gave 78% II [R = R¹ = Me (IV)], m. 85° (dilute EtOH). Similarly, I (R = Me, R¹ = Et, R² = H) and I [R = Et, R¹ = Me, R² = H (V)] with HNO₂ gave liquid II [R = Me, R¹ = Et (VI)] and II [R = Et, R¹ = Me (VII)], m. 63.5°, resp. IV, VI, and VII warmed 5 min. on a water bath with 10% NH₄OH were hydrolyzed to 85% I [R = R¹ = Me, R² = MeC(:NOH)C(:N)Me (VIII)], m. 202° (EtOH), 62% I [R = Me, R¹ = Et, R² = MeC(:NOH)C(:N)Et (IX)],m. 203.5°, and 100% I [R = Et, R¹ = Me, R² = EtC(:NOH)C(:N)Me (X)], m. 149°, resp. VIII, IX, and X were further hydrolyzed by dissolving in 30-40% H₂SO₄ to I [R = R¹ = Me, R² = MeC(:O)(:N)Me, m. 113°, I [R = Me, R¹ = Et, R² = MeC(:O)C(:N)Et, m. 95-7° (ligroine), and I [R = Et, R¹ = Me, R² = EtC(:O)C(:N)Me], m. 102-4°, resp. III in 10% HCl coupled with the appropriate diazonium chloride afforded liquid XI [R = o-NO₂ (XII)], XI [R = m-NO₂ (XIII)], m. 72°, and XI [R = p-NO₂ (XIV)], m. 91°. XII, XIII, and XIV were hydrolyzed in alc. 10% NH₄OH to MeC(:NOH)Ac (XV) o-nitrophenylhydrazone, m. 221° (decomposition), XV m-nitrophenylhydrazone, m. 257°, and XV p-nitrophenylhydrazone, m. 251°, resp. These results showed that Hanriot’s structure (Bull. Soc. Chim. France [3],5 776(1891)) for the product obtained from diazotizing V was incorrect. In the experiment, the researchers used many compounds, for example, Isoxazol-5-amine (cas: 14678-05-8Reference of 14678-05-8).

Isoxazol-5-amine (cas: 14678-05-8) belongs to isoxazole derivatives. Isoxazoles are aromatic heterocycles containing an N–O bond. The weakness of this bond allows the ring opening of these heterocycles under reductive conditions. Isoxazole can be synthesised via a variety of methods. Examples include via a 1,3-dipolar cycloaddition of nitrile oxides with alkynes.Reference of 14678-05-8

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

From Hit Seeking to Magic Bullets: The Successful Union of Epigenetic and Fragment Based Drug Discovery (EPIDD + FBDD) was written by Vaidergorn, Miguel M.;da Silva Emery, Flavio;Ganesan, A.. And the article was included in Journal of Medicinal Chemistry in 2021.Name: (S)-2-(6-(4-Chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide This article mentions the following:

We review progress in the application of fragment-based drug discovery (FBDD) to epigenetic drug discovery (EPIDD) targeted at epigenetic writer and eraser enzymes as well as reader domains over the last 15 years. The greatest successes to date are in prospecting for bromodomain binding ligands. From a diverse array of fragment hits, multiple potent and selective compounds ensued, including the oncol. clin. candidates mivebresib, ABBV-744, pelabresib, and PLX51107. In the experiment, the researchers used many compounds, for example, (S)-2-(6-(4-Chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide (cas: 1380087-89-7Name: (S)-2-(6-(4-Chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide).

(S)-2-(6-(4-Chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide (cas: 1380087-89-7) belongs to isoxazole derivatives. Isoxazoles present in various natural products and synthetic compounds of biological importance like antibacterial, antagonists, antiinflammatory, analgesics, and also show the applications in functional materials. Some alternative routes for the synthesis of isoxazoles have also been developed and reported. The 2-benzoyl-2-halo-2H-azirines provide 4-haloisoxazoles in good yields after heating in toluene at reflux temperature.Name: (S)-2-(6-(4-Chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Nitrogen-15 NMR spectroscopy. Part X. Nitrogen-15 NMR spectra of azoles with two heteroatoms was written by Chen, Ban Chin;Von Philipsborn, Wolfgang;Nagarajan, Kuppuswamy. And the article was included in Helvetica Chimica Acta in 1983.Related Products of 5765-44-6 This article mentions the following:

The ¹⁵N-NMR spectra of azoles, with natural isotope abundance, have been measured under different exptl. conditions, and chem. shifts are reported for imidazoles, pyrazoles, oxazoles, isoxazoles, thiazoles, and isothiazoles. General trends of substituent effects in this heterocyclic series are discussed based on the data of 67 substituted azoles, dihydro- and tetrahydroazoles. ¹⁵N, ¹H spin-coupling constants have been determined from spectra obtained by [¹H] → ¹⁵N polarization-transfer experiments, i.e. an application of INEPT and DEPT pulse sequences. Two-bond and three-bond coupling constants are fully assigned and are discussed in terms of the specific pathways in azoles. The potential of structural applications of the new data is illustrated for isomeric nitro-imidazoles and highly-substituted pyrazoles, and in the case of ring-chain tautomerism of 2-substituted tetrahydrooxazoles. In the experiment, the researchers used many compounds, for example, 5-Methylisoxazole (cas: 5765-44-6Related Products of 5765-44-6).

5-Methylisoxazole (cas: 5765-44-6) belongs to isoxazole derivatives. Isoxazole rings are found in some natural products, such as ibotenic acid and muscimol. Isoxazole can be synthesised via a variety of methods. Examples include via the reaction of hydroxylamine with 1,3-diketones or derivatives of propiolic acid.Related Products of 5765-44-6

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Sitaxsentan sodium for pulmonary hypertension was written by MacIntyre, Iain M.;Dhaun, Neeraj;Goddard, Jane;Webb, David J.. And the article was included in Drugs of Today in 2008.Name: Sodium (4-chloro-3-methylisoxazol-5-yl)((2-(2-(6-methylbenzo[d][1,3]dioxol-5-yl)acetyl)thiophen-3-yl)sulfonyl)amide This article mentions the following:

Sitaxsentan is the first oral endothelin receptor antagonist (ETRA) with high selectivity for the endothelin-A (ET_A) receptor to be approved for clin. use by regulatory agencies in Europe for the treatment of pulmonary arterial hypertension (PAH). Clin. trials have shown it to be well tolerated and to improve exercise tolerance, functional class and pulmonary hemodynamics in PAH, results which appear to be at least as good as those for the mixed ETRA bosentan. Importantly, compared to bosentan, sitaxsentan has a lower incidence of liver toxicity and no interaction with sildenafil, a drug commonly used in the management of PAH. Furthermore, there is increasing evidence to suggest that ETRAs may play an important role in the future management of a wide variety of other conditions, from hypertension and renal disease to connective tissue disease and cancer. In some of these conditions, ET_A selectivity may be an advantage. In the experiment, the researchers used many compounds, for example, Sodium (4-chloro-3-methylisoxazol-5-yl)((2-(2-(6-methylbenzo[d][1,3]dioxol-5-yl)acetyl)thiophen-3-yl)sulfonyl)amide (cas: 210421-74-2Name: Sodium (4-chloro-3-methylisoxazol-5-yl)((2-(2-(6-methylbenzo[d][1,3]dioxol-5-yl)acetyl)thiophen-3-yl)sulfonyl)amide).

Sodium (4-chloro-3-methylisoxazol-5-yl)((2-(2-(6-methylbenzo[d][1,3]dioxol-5-yl)acetyl)thiophen-3-yl)sulfonyl)amide (cas: 210421-74-2) belongs to isoxazole derivatives. Isoxazoles present in various natural products and synthetic compounds of biological importance like antibacterial, antagonists, antiinflammatory, analgesics, and also show the applications in functional materials. The most common methods for N–O bond cleavage in isoxazoles are hydrogenation with palladium or platinum catalysts or with Raney Ni. Recent developments have shown that Mo(CO)6 efficiently cleaves the N–O bond in isoxazoles.Name: Sodium (4-chloro-3-methylisoxazol-5-yl)((2-(2-(6-methylbenzo[d][1,3]dioxol-5-yl)acetyl)thiophen-3-yl)sulfonyl)amide

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF₁ receptor antagonists was written by Huang, Charles Q.;Wilcoxen, Keith M.;Grigoriadis, Dimitri E.;McCarthy, James R.;Chen, Chen. And the article was included in Bioorganic & Medicinal Chemistry Letters in 2004.Electric Literature of C4H5NO This article mentions the following:

A series of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines I [R¹ = Cl, O₂N, Me, F₃C, H₂N, HO, etc.; R² = H, Me, Cl, O₂N, H₂N, MeO, NO, etc.; R³, R⁴ = n-Pr, n-Bu, MeOCH₂CH₂, cyclopropylmethyl, PhCH₂] was designed and synthesized as antagonists for the corticotropin-releasing factor-1 (CRF₁) receptor. Several compounds such as I [R¹ = Me₂N; R² = Me; R³ = R⁴ = n-Pr; (II)] (K_i = 10 nM) exhibited good binding affinities at the CRF₁ receptor. In addition, II had adequate solubility in water. In the experiment, the researchers used many compounds, for example, 5-Methylisoxazole (cas: 5765-44-6Electric Literature of C4H5NO).

5-Methylisoxazole (cas: 5765-44-6) belongs to isoxazole derivatives.Synthetically, isoxazoles serve as valuable precursors for the construction of diverse molecules, including many natural products. Isoxazoles are potent isosteres of pyridine and have been found to inhibit voltage-gated sodium channels for pain control, for the construction of tetracycline antibiotic derivatives, and as a therapeutic agent for depression.Electric Literature of C4H5NO

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor was written by Zhao, Yujun;Zhou, Bing;Bai, Longchuan;Liu, Liu;Yang, Chao-Yie;Meagher, Jennifer L.;Stuckey, Jeanne A.;McEachern, Donna;Przybranowski, Sally;Wang, Mi;Ran, Xu;Aguilar, Angelo;Hu, Yang;Kampf, Jeff W.;Li, Xiaoqin;Zhao, Ting;Li, Siwei;Wen, Bo;Sun, Duxin;Wang, Shaomeng. And the article was included in Journal of Medicinal Chemistry in 2018.COA of Formula: C20H16ClN3O2 This article mentions the following:

We report the structure-based discovery of CF53 (28) as a highly potent and orally active inhibitor of bromodomain and extra-terminal (BET) proteins. By the incorporation of a NH-pyrazole group into the 9H-pyrimido[4,5-b]indole core, we identified a series of compounds that bind to BRD4 BD1 protein with K_i values of <1 nM and achieve low nanomolar potencies in the cell growth inhibition of leukemia and breast cancer cells. The most-promising compound, CF53, possesses excellent oral pharmacokinetic properties and achieves significant antitumor activity in both triple-neg. breast cancer and acute leukemia xenograft models in mice. Determination of the co-crystal structure of CF53 with the BRD4 BD1 protein provides a structural basis for its high binding affinity to BET proteins. CF53 is very selective over non-BET bromodomain-containing proteins. These data establish CF53 as a potent, selective, and orally active BET inhibitor, which warrants further evaluation for advanced preclin. development. In the experiment, the researchers used many compounds, for example, (S)-2-(6-(4-Chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide (cas: 1380087-89-7COA of Formula: C20H16ClN3O2).

(S)-2-(6-(4-Chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide (cas: 1380087-89-7) belongs to isoxazole derivatives. Isoxazoles are aromatic heterocycles containing an N–O bond. The weakness of this bond allows the ring opening of these heterocycles under reductive conditions. As with isoxazolines, isoxazoles may be cleaved using low-valent titanium obtained from the Kulinkovich reaction.This procedure affords enaminoketones from 2,4-substituted isoxazoles.COA of Formula: C20H16ClN3O2

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem